AstraZeneca’s in-development lung cancer pill extended progression-free survival by more than a year in new Phase II data, a positive sign for a drug the company believes can bring in $3 billion in annual sales at its peak.

…read more

Source: AstraZeneca’s ‘$3B’ lung cancer drug impresses in a Phase II race with Clovis